Seniors in Medicare are about to get landmark obesity drug coverage
Medicare is introducing landmark coverage for GLP-1 weight-loss drugs, reducing costs to $50 a month for eligible seniors starting July 1.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Medicare will soon provide coverage for obesity drugs, including those similar to Ozempic, for a monthly cost of $50. This new coverage is set to begin on July 1.
Coverage from CNBC, TODAY, MassLive, and OregonLive emphasizes the landmark nature of this accessibility and the specific $50 monthly price point. Reports focus on the availability of GLP-1 drugs for qualifying seniors.
Future developments involve determining which specific individuals qualify for the coverage and the process for accessing the drugs.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 3h ago.
Quick answers
When does the new Medicare coverage begin?
The coverage is scheduled to start on July 1.
How much will the weight-loss drugs cost under this plan?
The drugs will be available for $50 a month.
Which types of drugs are being covered?
Medicare will cover GLP-1 weight-loss drugs, described as Ozempic-style medications.
Coverage (5)
- Dr. Oz’s GLP-1 Bridge could work, but it isn’t a model for price controls The Hill · 5h ago
- Medicare will soon offer some older Oregonians weight loss drugs for $50 a month. Here’s how it works OregonLive.com · 5h ago
- Medicare to cover Ozempic-style weight loss drugs for $50 a month starting July 1: Who qualifies MassLive · 5h ago
- Medicare to Cover GLP-1 Weight-Loss Drugs For $50 a Month: See If You’re Eligible TODAY.com · 5h ago
- Seniors in Medicare are about to get landmark obesity drug coverage CNBC · 5h ago
Topics
Related trends
He Retired at 66 With a Pension. It Quietly Pushed Him Into the Top IRMAA Bracket for Life.
Retirees are discovering how pensions and home sales can unexpectedly trigger high-income Medicare premium surcharges known as IRMAA.
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
Employers are reconsidering coverage for popular GLP-1 weight loss drugs, leaving patients and insurers in limbo.
Lilly, J&J and AbbVie Hit New Highs
Lilly, Johnson & Johnson and AbbVie stocks reach unprecedented levels as investors shift from tech to healthcare.
GLP-1 weight loss drugs may be misused by patients with eating disorders: Study
New research indicates that GLP-1 receptor agonists, including Ozempic, are being misused by individuals with eating disorders.
The Wearable Data Your Doctor Actually Wants
Doctors are increasingly interested in wearable data to inform patient care.
Most IVF ‘add-on’ treatments have no effect on fertility or remain unproven, study says
A new study questions the effectiveness of many IVF add-on treatments, sparking debate in fertility circles.